ATF6 and neoplasm: Furthermore, our clinical results identified approximately 11% of CRC patients from all tumor stages who overexpressed ATF6, and linked increased ATF6 levels in tumors of a subset of CRC patients with increased risk of post-operative disease relapse, supporting our hypothesis that ATF6 represents a novel and clinically relevant tumor risk gene defining a subgroup of CRC patients.